The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 29th Conference on Retroviruses and Opportunistic Infections (AIDS 2022). This program consists of two components: (1) CME Internet Symposium: AIDS 2022 Expert Review: a 1.5-hour Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; and (2) AIDS 2022 e-Newsletter: a brief on-line summary of the most essential data presented at the conference.
The AIDS 2022 e-Newsletter features a portable electronic summary of key presentations and data presented at the conference. This activity will quickly enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This program is jointly provided by Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2022 and it is not sanctioned by the organizers of AIDS 2022.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
Release Date: August 12, 2022
Expiration Date: August 12, 2023
Estimated time to complete the program: 30 minutes
Type of hardware/softward needed to participate in activity: PC/Mac/tablet/smartphone with internet browser
|
Renslow Sherer, MD |
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:
Renslow Sherer, MD
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 17105 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) Complete the online Evaluation
7) Receive an immediate CE Certificate to download and/or print for your files
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by independent educational grants from Gilead Sciences Medical Affairs and Janssen Therapeutics, Division of Janssen Products LP
